Replikins boasts of new swine flu jab; Gardasil sales flatten in Europe;

Vaccine Research

Boston-based Replikins says that it has already developed a synthetic H1N1 vaccine and can produce it 100 times faster than the competition. Report

Lipoxen PLC has received funding to apply its ImuXen technology to enhance the performance of malaria vaccine candidates. Release

A potential vaccine for Alzheimer's disease also has been shown in mice to slow the weakening of muscles associated with inclusion body myositis, a disorder that affects the elderly. Release

Scientists at Baylor Institute for Immunology Research in Dallas received a renewal of a multi-million dollar grant from the National Institutes of Health to design new vaccines to prevent influenza--including swine flu. Release

Vaccine Market

Sales of Merck's Gardasil are expected to be flat in Europe as demand from early adopter countries levels off. Report

McKesson says that it will store 500,000 doses of flu vaccine for the CDC. Report

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.